
|Articles|June 16, 2020
Pratia and KFGN Join Forces
Advertisement
Pratia Inc has claimed 40% shares in KFGN, with an overall investment plan that assumes increased shareholding up to a clear majority position in the upcoming years. Dr. Ole Dammann will continue his leadership as CEO of KFGN. Additionally, as a Board Member of Pratia, he will support international growth of Site Network.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
2
What the Epilepsy Community Has Taught Us About Trial Feasibility
3
The Evolution of Preclinical CRO Strategic Partnerships: From Transactional Services to Value-Driven Ecosystems in 2026
4
Lab Orchestration Is Not What You Think It Is
5




